Gene Expression Profiling of Breast Cancer: A New Tumor Marker
- 10 March 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (8), 1631-1635
- https://doi.org/10.1200/jco.2005.12.005
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Expression of FGF-2 alters focal adhesion dynamics in migration-restrictedBreast Cancer Research and Treatment, 2004
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast CancerJournal of Clinical Oncology, 2004
- E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and CyclophosphamideBreast Cancer Research and Treatment, 2003
- Predictive Molecular PathologyNew England Journal of Medicine, 2002
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular classification of breast cancer patients by gene expression profiling*The Journal of Pathology, 2001
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI Journal of the National Cancer Institute, 1996